Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID) - University of Regensburg Publication Server

URN to cite this document:: urn:nbn:de:bvb:355-epub-344728
DOI to cite this document:: 10.5283/epub.34472

Witt, M. ; Grunke, M. ; Proft, F. ; Bäuerle, M. ; Aringer, M. ; Burmester, G. ; Chehab, B. ; Fiehn, C. ; Fischer-Betz, R. ; Fleck, Martin

Preview

License: Allianz- bzw. Nationallizenz
PDF - Published Version
(242kB)

Date of publication of this fulltext: 26 Aug 2016 05:35

Alternative links to fulltext:DOI

Details

Preview

Export bibliographical data

Abstract

Objective The objective of this article is to evaluate the safety and clinical outcome of rituximab treatment in systemic lupus erythematosus (SLE) patients refractory to standard of care therapy in a real-life setting in Germany. Methods The GRAID registry included patients with different autoimmune diseases who were given off-label treatment with rituximab. Data on safety and clinical response ...